2023
Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments
Krystal J, Kaye A, Jefferson S, Girgenti M, Wilkinson S, Sanacora G, Esterlis I. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2305772120. PMID: 38011560, PMCID: PMC10710048, DOI: 10.1073/pnas.2305772120.Peer-Reviewed Original Research
2022
Prefrontal Glutamate Neurotransmission in PTSD: A Novel Approach to Estimate Synaptic Strength in Vivo in Humans
Averill LA, Jiang L, Purohit P, Coppoli A, Averill CL, Roscoe J, Kelmendi B, De Feyter HM, de Graaf RA, Gueorguieva R, Sanacora G, Krystal JH, Rothman DL, Mason GF, Abdallah CG. Prefrontal Glutamate Neurotransmission in PTSD: A Novel Approach to Estimate Synaptic Strength in Vivo in Humans. Chronic Stress 2022, 6: 24705470221092734. PMID: 35434443, PMCID: PMC9008809, DOI: 10.1177/24705470221092734.Peer-Reviewed Original ResearchGlutamatergic synaptic strengthSynaptic strengthPathophysiology of PTSDNovel putative biomarkersTrauma-related psychopathologyMagnetic resonance spectroscopyGlutamate neurotransmissionHealthy controlsNew treatmentsChronic stressPatientsPutative biomarkersEffects of sexPTSDNeurotransmissionPosttraumatic stressAgePsychopathologyEPCPathophysiologyStudy resultsTraumaBiomarkers
2018
2. MICROCIRCUITS, MACROCIRCUITS, AND CORTICOL DYSFUNCTION IN SCHIZOPHRENIA: A COMPUTATIONAL AND TRANSLATIONAL NEUROSCIENCE PERSPECTIVE
Krystal J. 2. MICROCIRCUITS, MACROCIRCUITS, AND CORTICOL DYSFUNCTION IN SCHIZOPHRENIA: A COMPUTATIONAL AND TRANSLATIONAL NEUROSCIENCE PERSPECTIVE. Schizophrenia Bulletin 2018, 44: s1-s1. PMCID: PMC5887654, DOI: 10.1093/schbul/sby014.001.Peer-Reviewed Original ResearchNMDA glutamate receptorsNMDA receptor antagonistCortical functional connectivityPathophysiology of schizophreniaReceptor antagonistTranslational neuroscience perspectiveGlutamate receptorsHealthy humansAnimal modelsSchizophrenia patientsMemory impairmentNeuropsychiatric disordersSynaptic signalingFunctional connectivityNovel therapeuticsSchizophreniaDisordersPresentationPatientsPathophysiologyDysfunctionKetamineAntagonistSymptomsAbnormalities
2017
Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic
Krystal JH, Abdallah CG, Averill LA, Kelmendi B, Harpaz-Rotem I, Sanacora G, Southwick SM, Duman RS. Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic. Current Psychiatry Reports 2017, 19: 74. PMID: 28844076, PMCID: PMC5904792, DOI: 10.1007/s11920-017-0829-z.Peer-Reviewed Original ResearchConceptsSynaptic connectivityRapid-acting treatmentPathophysiology of PTSDPotential clinical importanceTreatment of PTSDSynaptic lossPurpose of ReviewStudiesDisconnection syndromeClinical importanceNovel pharmacotherapeuticsNovel therapeuticsPTSD symptomsRecent FindingsHerePTSDPathophysiologyKetamineTreatmentDisordersTherapeutic applicationsStress-related lossesSyndromeSymptomsPharmacotherapeutics
2016
PTSD: from neurobiology to pharmacological treatments
Kelmendi B, Adams TG, Yarnell S, Southwick S, Abdallah CG, Krystal JH. PTSD: from neurobiology to pharmacological treatments. European Journal Of Psychotraumatology 2016, 7: 31858. PMID: 27837583, PMCID: PMC5106865, DOI: 10.3402/ejpt.v7.31858.Peer-Reviewed Original ResearchPosttraumatic stress disorderPharmacological treatmentPathophysiology of PTSDFirst-line pharmacotherapyMultiple neurobiological systemsEtiology of PTSDFull remissionTherapeutic effectPsychiatric disordersPharmacologic targetStress disorderNeurobiological systemsPathophysiologyFuture targetsTreatmentTraumatic eventsDisordersRemissionPharmacotherapyEtiologyInjurySymptomsYearsWeeks
2015
Deconstructing N-Methyl-D-Aspartate Glutamate Receptor Contributions to Cortical Circuit Functions to Construct Better Hypotheses About the Pathophysiology of Schizophrenia
Krystal JH. Deconstructing N-Methyl-D-Aspartate Glutamate Receptor Contributions to Cortical Circuit Functions to Construct Better Hypotheses About the Pathophysiology of Schizophrenia. Biological Psychiatry 2015, 77: 508-510. PMID: 25687430, DOI: 10.1016/j.biopsych.2014.10.010.Peer-Reviewed Original Research
2010
Neurotransmitter Systems in Bipolar Disorder
Nakic M, Krystal J, Bhagwagar Z. Neurotransmitter Systems in Bipolar Disorder. 2010, 210-227. DOI: 10.1002/9780470661277.ch16.Peer-Reviewed Original Research
2007
Probing the Pathophysiology of Auditory/Verbal Hallucinations by Combining Functional Magnetic Resonance Imaging and Transcranial Magnetic Stimulation
Hoffman RE, Hampson M, Wu K, Anderson AW, Gore JC, Buchanan RJ, Constable RT, Hawkins KA, Sahay N, Krystal JH. Probing the Pathophysiology of Auditory/Verbal Hallucinations by Combining Functional Magnetic Resonance Imaging and Transcranial Magnetic Stimulation. Cerebral Cortex 2007, 17: 2733-2743. PMID: 17298962, PMCID: PMC2634833, DOI: 10.1093/cercor/bhl183.Peer-Reviewed Original ResearchConceptsRepetitive transcranial magnetic stimulationTranscranial magnetic stimulationFunctional magnetic resonance imagingMagnetic resonance imagingMagnetic stimulationSham stimulationTemporoparietal repetitive transcranial magnetic stimulationAuditory/verbal hallucinationsResonance imagingWernicke's areaVerbal hallucinationsBOLD signal time coursesBroca's areaSchizophrenia spectrum disordersGreater rateInferior frontal regionsPatientsTemporoparietal areasSignal time courseCortical sitesPathophysiologySupramarginal gyrusHallucinationsRight homologueStimulation
2005
GABA and glutamate systems as therapeutic targets in depression and mood disorders
Kendell SF, Krystal JH, Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opinion On Therapeutic Targets 2005, 9: 153-168. PMID: 15757488, DOI: 10.1517/14728222.9.1.153.Peer-Reviewed Original Research
2004
Cannabinoid ‘model’ psychosis, dopamine–cannabinoid interactions and implications for schizophrenia
D'souza D, Cho H, Perry E, Krystal J. Cannabinoid ‘model’ psychosis, dopamine–cannabinoid interactions and implications for schizophrenia. 2004, 142-165. DOI: 10.1017/cbo9780511543630.012.Peer-Reviewed Original ResearchReceptor dysfunctionCannabinoid compoundsCannabis consumptionPathophysiology of psychosisPathophysiology of schizophreniaRecent pharmacological studiesPrincipal psychoactive constituentEffects of exposurePostmortem studiesNormal controlsPsychotic symptomsPsychotic disordersPharmacological studiesPsychosisPsychoactive constituentPathophysiologyΔ9-tetrahydrocannabinolSchizophreniaCannabisDysfunctionAssociationPossible mechanismPatientsSymptomsPharmacological
2003
Clinical Studies Implementing Glutamate Neurotransmission in Mood Disorders
SANACORA G, ROTHMAN DL, MASON G, KRYSTAL JH. Clinical Studies Implementing Glutamate Neurotransmission in Mood Disorders. Annals Of The New York Academy Of Sciences 2003, 1003: 292-308. PMID: 14684453, DOI: 10.1196/annals.1300.018.Peer-Reviewed Original Research
2001
CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERS
Krystal J, D'Souza D, Sanacora G, Goddard A, Charney D. CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERS. Medical Clinics Of North America 2001, 85: 559-577. PMID: 11349473, DOI: 10.1016/s0025-7125(05)70329-1.Peer-Reviewed Original Research
1999
Comparison of four components of sensory gating in schizophrenia and normal subjects: a preliminary report
Boutros N, Belger A, Campbell D, D’Souza C, Krystal J. Comparison of four components of sensory gating in schizophrenia and normal subjects: a preliminary report. Psychiatry Research 1999, 88: 119-130. PMID: 10622348, DOI: 10.1016/s0165-1781(99)00074-8.Peer-Reviewed Original ResearchConceptsNormal control subjectsSchizophrenia patientsSensory gatingControl subjectsNormal subjectsSex-matched normal control subjectsPathophysiology of schizophreniaStimulus repetitionStable schizophrenia patientsSchizophrenia subjectsSimilar abnormalitiesPatientsPreliminary reportDysfunctionDegree of attenuationSchizophreniaLate phaseSubjectsDeviant stimuliStimulus changeIrrelevant stimuliPathophysiologyStimuliPotential paradigmAbnormalities
1997
The role of serotonin in the pathophysiology and treatment of schizophrenia
Abi-Dargham A, Laruelle M, Aghajanian GK, Charney D, Krystal J. The role of serotonin in the pathophysiology and treatment of schizophrenia. Journal Of Neuropsychiatry 1997, 9: 1-17. PMID: 9017523, DOI: 10.1176/jnp.9.1.1.Peer-Reviewed Original ResearchConceptsRole of serotoninBeneficial effectsSubcortical dopamine activityCerebrospinal fluid studiesCortex of patientsTreatment of schizophreniaBrain tissue analysisSerotonergic hypofunctionDopaminergic antagonistsPharmacological challengeDopamine activityNegative symptomsFluid studiesSchizophreniaPathophysiologySerotoninIllnessTissue analysisTreatmentMore researchAntagonismCompelling evidenceHypofunctionPatientsAntagonist
1990
Serotonin-Specific Drugs for Anxiety and Depressive Disorders
Charney DS, Krystal JH, Delgado PL, Heninger GR. Serotonin-Specific Drugs for Anxiety and Depressive Disorders. Annual Review Of Medicine 1990, 41: 437-446. PMID: 2139556, DOI: 10.1146/annurev.me.41.020190.002253.Peer-Reviewed Original Research
1989
Neurobiological aspects of PTSD: Review of clinical and preclinical studies
Krystal J, Kosten T, Southwick S, Mason J, Perry B, Giller E. Neurobiological aspects of PTSD: Review of clinical and preclinical studies. Behavior Therapy 1989, 20: 177-198. DOI: 10.1016/s0005-7894(89)80068-1.Peer-Reviewed Original Research